Apogee Therapeutics to Participate in Upcoming Conferences

Rhea-AI Summary

Apogee Therapeutics (Nasdaq: APGE) announced management will participate in five investor conferences in November–December 2025 with scheduled fireside chats and webcasts.

Conferences and times: Guggenheim Healthcare – Nov 11, 2025 at 1:30 p.m. ET; Stifel Healthcare – Nov 12, 2025 at 11:20 a.m. ET; TD Cowen Immunology & Inflammation Virtual Summit – Nov 13, 2025 at 12:30 p.m. ET; Jefferies London Healthcare – Nov 19, 2025 at 3:00 p.m. GMT / 10:00 a.m. ET; Citi Global Healthcare – Dec 3, 2025 at 9:45 a.m. ET.

A live and archived webcast of the fireside chats will be available on the company’s Investors & News & Events webpage.

SAN FRANCISCO and BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate at the following investor conferences.

Guggenheim 2^nd Annual Healthcare Innovation Conference 
Date: Tuesday, November 11, 2025
Fireside Chat Time: 1:30 p.m. ET

Stifel 2025 Healthcare Conference
Date: Wednesday, November 12, 2025
Fireside Chat Time: 11:20 a.m. ET

TD Cowen Immunology and Inflammation Virtual Summit  
Date: Thursday, November 13, 2025
Fireside Chat Time: 12:30 p.m. ET

Jefferies London Healthcare Conference 
Date: Wednesday, November 19, 2025
Fireside Chat Time: 3:00 p.m. GMT / 10:00 a.m. ET

Citi 2025 Global Healthcare Conference 
Date: Wednesday, December 3, 2025
Fireside Chat Time: 9:45 a.m. ET

A live and archived webcast of the fireside chats will be available via the News & Events page in the Investors section of the Apogee Therapeutics website.

About Apogee
Apogee Therapeutics is a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest I&I markets, including for the treatment of Atopic Dermatitis (AD), asthma, Eosinophilic Esophagitis (EoE), Chronic Obstructive Pulmonary Disease (COPD), and other I&I indications. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class profiles through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the Company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care.

Investor Contact:
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics, Inc.
noel.kurdi@apogeetherapeutics.com

Media Contact:
Dan Budwick
1AB
dan@1abmedia.com

FAQ

When will Apogee Therapeutics (APGE) present at Guggenheim 2025?

Apogee will present at the Guggenheim 2nd Annual Healthcare Innovation Conference on Nov 11, 2025 with a fireside chat at 1:30 p.m. ET.

How can investors watch Apogee Therapeutics (APGE) fireside chats from November 2025?

A live and archived webcast will be available via the company’s Investors & News & Events webpage.

What time is Apogee's Jefferies London Healthcare fireside chat on Nov 19, 2025?

The Jefferies London Healthcare fireside chat is scheduled for Nov 19, 2025 at 3:00 p.m. GMT / 10:00 a.m. ET.

Which conferences will Apogee Therapeutics (APGE) attend in Nov–Dec 2025?

Apogee will attend Guggenheim (Nov 11), Stifel (Nov 12), TD Cowen Virtual Summit (Nov 13), Jefferies London (Nov 19), and Citi Global Healthcare (Dec 3).

What is the scheduled time for Apogee's Stifel 2025 Healthcare Conference presentation?

The Stifel 2025 Healthcare Conference fireside chat is set for Nov 12, 2025 at 11:20 a.m. ET.